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various conditions, a common pattern of events can be 
suggested, including periostin localization during develop-
ment, insult and injury, epithelial–mesenchymal transition, 
extracellular matrix restructuring, and remodeling. we pro-
pose mesenchymal remodeling as an overarching role for 
the matricellular protein periostin, across physiology and 
disease. Periostin may be seen as an important structural 
mediator, balancing appropriate versus inappropriate tissue 
adaption in response to insult/injury.
Keywords Periostin · extracellular matrix · Remodeling · 
Repair
Introduction
Periostin, also termed osteoblast-specific factor 2, is a 
93.3 kDa-secreted, vitamin K-dependent glutamate-con-
taining matricellular protein, originally isolated from a 
Abstract Periostin, also termed osteoblast-specific fac-
tor 2, is a matricellular protein with known functions in 
osteology, tissue repair, oncology, cardiovascular and res-
piratory systems, and in various inflammatory settings. 
However, most of the research to date has been conducted 
in divergent and circumscribed areas meaning that the 
overall understanding of this intriguing molecule remains 
fragmented. Here, we integrate the available evidence 
on periostin expression, its normal role in development, 
and whether it plays a similar function during pathologic 
repair, regeneration, and disease in order to bring together 
the different research fields in which periostin investiga-
tions are ongoing. In spite of the seemingly disparate roles 
of periostin in health and disease, tissue remodeling as a 
response to insult/injury is emerging as a common func-
tional denominator of this matricellular molecule. Periostin 
is transiently upregulated during cell fate changes, either 
physiologic or pathologic. Combining observations from 
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mouse osteoblast cell line [1, 2]. It is encoded by the Postn 
gene (genebank D13664) in humans, and to date, trans-
forming growth factor beta (TGF-β) 1, 2, and 3, bone mor-
phogenetic proteins (BMP) 2 and 4, vascular endothelial 
growth factor, connective tissue growth factor 2, vitamin 
K, valsartan (an angiotensin II antagonist), and interleukin 
(IL) 3, 4, 6, and 13 have all been reported to induce peri-
ostin expression in a cell-specific context [3].
Periostin is assigned to the family of fasciclins based on 
its homology to fasciclin I (FAS1), initially identified in 
insects. Proteins that share homology with FAS1 include β 
ig-h3, stablin I and II, MBP-70, Algal-CAM, periostin, and 
periostin-like-factor 1 and 2 [1, 2, 4–8]. The four internal 
repeat regions of periostin share homology with an axon 
guidance protein FAS1, containing sequences that allow 
binding of integrins and glycosaminoglycans in vivo [9]. At 
the N-terminus, periostin has an eMI domain, which is a 
small cysteine-rich module of ~75 amino acids. The eMI 
domain was first named after its presence in proteins of the 
eMILIN family and is associated with other domains, such 
as C1q, laminin-type eGF-like, FN3, wAP, ZP, or FAS1 
[10, 11].
In keeping with periostin’s matricellular role as having 
regulatory rather than structural functions, periostin can 
interact with αv-integrins, induce activation of NF-κB/
STAT3 [12–14], PI3K/Akt [15], and FAK signaling [16], 
and modulate expression of multiple downstream genes 
including: α-smooth muscle actin (αSMA), collagen, 
fibronectin, aggrecan, sclerostin, chemokines, and TGF-β1 
[17–20].
Although periostin has been the target of a multitude of 
scientific publications since its first identification in 1993 
[1, 2], almost all of the research has been conducted in nar-
rowly defined areas. while considerable in-depth molecu-
lar knowledge on periostin is evolving in selected fields 
[21], the overall understanding of this intriguing molecule 
remains fragmented. As a matricellular protein, periostin 
has defined functions in osteology, tissue repair, oncol-
ogy, cardiovascular and respiratory systems, and in vari-
ous inflammatory settings and diseases. extensive research 
has helped to elucidate its mechanism of action or role in 
many of these, yet there remain several disease states for 
which its mechanism of action is still unresolved. emerg-
ing data associates periostin with Th2-associated inflamma-
tory diseases, sparking research in several atopic conditions 
including bronchial asthma. Furthermore, although several 
different splice variants of periostin have been described 
[3, 22, 23], their functional implications are as yet not fully 
understood. Potentially, distinct splice forms may be asso-
ciated with different functions in various tissues and dis-
ease states.
The aim of this review is to (1) integrate the diverse evi-
dence for the role of periostin across health and disease, 
and (2) identify an overarching mode of action for this plei-
otropic matricellular molecule.
Role of periostin in health and disease
An overarching mode of action is not obviously apparent 
and has not been described to date in the wide range of 
tissues and diseases in which periostin has been reported. 
However, a closer analysis of the associated literature, 
detailed here, reveals a commonality related to structural 
remodeling as an upregulated responder to stress/challenge 
stimuli, regardless of physiology or disease. In this paper, 
we summarize the available evidence on periostin expres-
sion, its normal role in development, and whether it plays 
a similar function during pathologic repair, regeneration, 
and disease in order to bring together the disparate research 
fields in which periostin investigations are ongoing.
Osteology
Osteoblast-specific factor 2 was identified in 1993 in pre-
osteoblasts and assigned a role in cell adhesion [2]. It was 
renamed periostin because of high levels of expression in 
the periosteum; the layer of connective tissue surrounding 
bone and responsible for intramembranous bone growth 
required for the increase in bone diameter, which is related 
to bone strength. Periostin is also highly expressed in the 
periodontal ligament (PDL) surrounding teeth and respon-
sible for attaching them to the underlying bone [8, 24–27]. 
The PDL is the conduit for transmission of load to the 
bony mandible or maxilla and consequently is an impor-
tant structure required to maintain healthy dentition and 
bone. In periostin (Postn) −/− mice, collagen fibrillogen-
esis was disrupted in the periosteum and studies on osteo-
blasts isolated from calvaria of these mice suggest a role in 
extracellular matrix (eCM) organization as well [28, 29]. 
It is well recognized that both the bone and the ligament 
surrounding teeth respond to mechanical stress by remod-
eling. However, in Postn −/− mice, mechanical loading 
resulted in disorganized collagen matrix formation and 
an increase in sclerostin mRNA suggesting a sclerostin-
mediated decrease in bone mass in these animals. Moreo-
ver, bone architecture in response to mechanical stress was 
restored with anti-sclerostin blocking antibody injections in 
these animals [19]. Therefore, under normal circumstances, 
periostin expression results in reduced sclerostin, thereby 
preserving bone mass and promoting bone remodeling. In 
the absence of periostin, the increase in sclerostin results 
in aberrant bone remodeling and a decrease in bone mass. 
However, as tendons are key in transmitting the force of 
contraction from muscle to bone, it is possible that in peri-
ostin null mice, tendon collagen organization is disrupted, 
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interfering with effective transfer of force contraction 
from muscle to bone. Bone remodeling is then negatively 
affected in the absence of adequate loading (force). As the 
PDL performs an analogous function in teeth as do tendons 
in bone, findings from the loss of periostin in the knock-
out mouse in both of these tissues suggest a crucial role for 
periostin in mechanotransduction and response to mechani-
cal loading and stress.
During embryogenesis and in the neonate, periostin 
isoforms are expressed in a specific temporal and spatial 
pattern, suggesting different functions for these variants 
in bone development and maturation [24]. In adults, peri-
ostin is re-expressed during fracture repair or in response 
to mechanical stress when bone development and remod-
eling is required [30]. A complete picture of the differential 
expression of the periostin isoforms is needed to understand 
the role of the variants in bone development, maturation, 
and repair. In vitro findings suggest that periostin’s action 
on bone formation is through an increase in osteoblast pro-
liferation, differentiation, adhesion, and survival [31]. The 
absence of periostin in knockout mouse models results in 
growth retardation and dwarfisms, shorter long-bones, and 
aberrant epiphyseal plate organization [19, 25], suggesting a 
role for periostin in bone development/remodeling and bone 
strength. Periostin mediates its effects on bone remodeling 
specifically by regulating collagen crosslinking and fibrillo-
genesis by binding to BMP1 via the eMI domain [32], or 
under conditions of mechanical stress by binding to Notch 1 
and impacting osteoblast differentiation and cell death [33, 
34]. In pathology, the expression of periostin is observed in 
fibrous dysplasia, a benign bone disease [35].
Cutaneous and connective tissue remodeling
Tissue regeneration in response to insult is associated with 
increased periostin expression [12]. However, this phenom-
enon is only transient, starting a few days post-injury, with 
protein levels peaking after 7 days and mRNA levels increas-
ing slightly beforehand. Repetitive strain injuries have been 
associated with excess collagen deposition around myofib-
ers, cell necrosis, infiltration of inflammatory cells, and 
increased cytokine expression. In addition, tendon and neural 
injuries can occur, leading to subsequent chronic inflamma-
tory responses, followed by residual fibrosis [28, 36]. A per-
iostin-like-factor was located in satellite cells and/or myo-
blasts, which increased in expression with continued task 
performance, supporting the hypothesis of a role in muscle 
repair and/or regeneration [37]. Furthermore, periostin has 
been shown to be expressed at basal levels in healthy human 
skin but localizes to the extracellular compartment during 
tissue remodeling involved in wound repair [38]. Recent 
studies indicate the contribution of periostin toward dermal 
regeneration and wound healing, suggesting that periostin 
may promote defect closure by facilitating the activation, dif-
ferentiation, and contraction of fibroblasts [12, 13, 39].
Oncology
Periostin overexpression is observed in various types of 
cancer [40], including thymoma [41], non-small cell lung 
carcinoma [42], breast cancer [43], pancreatic ductal 
adenocarcinoma [44], and in ascites from ovarian cancer 
patients [45]. It is believed to play a role during invasion, 
angiogenesis, and metastasis, as demonstrated by in vitro 
and in vivo experiments [40].
Solid tumor cells express high levels of periostin, yet the 
function of this matricellular protein during non-solid tumo-
rigenesis and progression remains unclear. Periostin has 
been reported to promote tumor angiogenesis, migration, 
and metastases [46], and its overexpression has been shown 
to enhance invasion and anchorage-independent growth and 
spread in oral squamous-cell carcinoma [47]. Bao et al. [48] 
demonstrated that a colon cancer cell line with low meta-
static potential, transduced to overexpress periostin, displayed 
accelerated metastatic growth, and that periostin activated 
the Akt/PKB pathway via the αvβ3 integrin to promote can-
cer cell survival. Supporting these observations, retrospective 
analyses of clinical studies have also shown that periostin 
expression is associated with a trend to metastasize and cor-
relates with angiogenesis in oral, breast, and colon cancers 
[46, 48–50]. Furthermore, targeting periostin with a modi-
fied DNA aptamer, PNDA-3, that is capable of binding to 
periostin with high affinity and inhibiting its function, mark-
edly antagonized adhesion, migration, and invasion of breast 
cancer cells both in vitro and in an in vivo orthotopic mouse 
breast cancer model [51]. Recent findings also suggest that 
periostin may have a role in sprouting neovascular endothelial 
tips of disseminated tumor cells, promoting breast cancer cell 
outgrowth in a tumor-suppressive microenvironment [52].
Periostin is a driver of the epithelial–mesenchymal tran-
sition (eMT) and induces expression of MMP-9, MMP-
10, and MMP-13, resulting in the degradation of eCM, 
believed to be crucial for local tumor spread and/or metas-
tasis [53–55]. Furthermore, it is involved in remodeling the 
tumor microenvironment, which in turn promotes tumor 
survival, growth, and invasiveness [47]. This has also been 
described in the pancreatic parenchyma, in which periostin 
creates a tumor-supportive niche by sustaining fibrogenic 
stellate cell activity [17, 56], and in esophageal cancer, in 
which periostin facilitates tumor invasion [57, 58]. Stromal 
periostin has also been indicated to play a critical role in 
metastatic colonization [59–61], by regulating the interac-
tions between cancer stem cells and their metastatic niche. 
Moreover, stromal periostin has recently been reported to 
enhance cell attachment of clear cell renal cell carcinoma 
and proliferation of fibroblasts [62]. Periostin may bridge 
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the gap between the metastatic microenvironment and can-
cer stem cells to promote metastatic spread by augmenting 
the wnt signaling pathway [59, 60]. Interestingly, periostin 
is highly expressed in human bone marrow mesenchymal 
stem cells and their derived adipocytes, chondrocytes, and 
osteoblasts. Periostin-overexpressing human mammary epi-
thelial cells acquire part of the multi-lineage differentiation 
potentials of mesenchymal stem cells and promote tumor 
growth and metastasis of human breast cancer cell line 
[63]. These data indicate that periostin is a critical matricel-
lular component in remodeling tissue microenvironment in 
tumor growth and metastasis.
Cardiovascular
Periostin is central in cardiovascular differentiation during 
in utero development of the cardiac valves and fibrous heart 
skeleton, and is re-expressed following myocardial injury. In 
detail, it promotes cardiac mesenchymal stem cell differenti-
ation into fibrogenic lineages, is inhibitory to non‐fibrogenic 
differentiation, and supports early valvulogenesis [18]. Dur-
ing neonatal remodeling, peak expression of periostin will 
induce collagen production, compaction, and fibroblast 
proliferation, mediating increased ventricular wall stiffness 
and valve functional maturation. In Postn −/− mice, post-
natal valve leaflets are truncated, interspersed with ectopic 
cardiomyocytes and smooth muscle, show impaired eCM 
composition, and exhibit reduced TGF-β signaling [64]. 
Additionally, periostin is robustly expressed during annulus 
fibrosus development and abnormalities of this differentia-
tion process may underlie development of certain forms of 
re-entrant atrioventricular tachycardia [65]. However, peri-
ostin is downregulated in the postnatal cardiac fibroblast lin-
eage and remains at a low level of expression, but can be 
rapidly upregulated within cardiac fibroblast/myofibroblasts 
in response to insult/injury. It is robustly increased follow-
ing pressure overload-induced left ventricular hypertrophy, 
and in turn downregulated after left ventricular hypertrophy 
regression in both animal and human models [66]. Simi-
larly, periostin was markedly upregulated in mouse models 
of hypertrophic cardiomyopathy associated with non-myo-
cyte proliferation and fibrosis. Abrogating periostin or TGF-
β reduced or extinguished both proliferation and fibrosis 
and improved heart function [67].
In adult pathologic remodeling following cardiac injury 
or hypertension, periostin serum levels increase and are 
linked to accelerated mobilization, tissue engraftment, and 
differentiation of bone marrow cells into cardiac fibroblasts 
[68]. Additionally, genetic manipulation of Postn within 
the mouse has demonstrated that periostin itself within 
the heart does not affect myocyte content and cell cycle 
activity, but may facilitate scarless healing [69]. As a con-
sequence, Postn −/− mice are more prone to ventricular 
rupture within the first 10 days after myocardial infarction 
[22], yet survivors showed less fibrosis and better ventricu-
lar performance. Furthermore, inducible periostin overex-
pression protected mice from rupture following myocardial 
infarction but induced spontaneous hypertrophy with aging 
[70]. Periostin deposition has also been demonstrated to 
be involved in repair after vascular injury [71], and there 
is evidence that periostin insufficiency may contribute to 
valvular heart disease [3, 72], heart failure [66, 73], and 
atherosclerosis [74]. elevated periostin in both normal and 
pathologic hearts is confined to the cardiac fibroblast (non‐
cardiomyocyte) lineages, with TGF-β2 being required for 
periostin expression [75]. Thus, Postn is currently being 
discussed as a potential target for prevention of heart fail-
ure [66, 73].
Allergic and respiratory diseases
Periostin has been reported to play a role in neonatal lung 
remodeling. Prolonged hyperoxic lung injury was shown to 
upregulate periostin, stimulating ectopic accumulation of 
myofibroblasts expressing αSMA, and leading to alveolar 
simplification [76]. Indeed, periostin expression is tightly 
correlated with the presence of αSMA-myofibroblasts, and 
its dysregulation may be a sensitive indicator of acutely-
inhibited alveolar septation during a crucial window of 
lung remodeling [77].
It is evident that epithelial damage is commonplace in 
respiratory disease, be it from allergens or viral or bacte-
rial infection. In the lung, periostin expression decreases 
following acute injury, but then increases substantially fol-
lowing TGF-β activation and the initiation of repair mecha-
nisms, but this may persist beyond the initial insult. evi-
dence suggests a close relationship between periostin and 
fibrogenesis in response to pulmonary injury [78].
There is a growing body of evidence regarding the role 
of periostin in asthma and type 2 inflammatory responses 
in particular [79–81]. Asthma symptoms in some patients 
may be exacerbated by chronic inflammation of the air-
ways, largely mediated by type 2 inflammatory cytokines, 
in particular IL-13, which is produced by a variety of adap-
tive and innate immune cell types including CD4+ T cells, 
mast cells, basophils, and the recently described innate Th2 
cells (ILC2) [82–85]. IL-13 and IL-4 can stimulate the pro-
duction of periostin via activation of signal transducer and 
activator of transcription-6 (STAT6) [79, 80, 86]. Periostin 
expression is elevated in the bronchial epithelial cells of a 
subset of patients with asthma and is secreted basolater-
ally [79, 86]. Periostin localizes to the basement membrane 
zone and the mesenchymal tissue compartment in the lung 
and colocalizes with other eCM proteins such as colla-
gen, fibronectin, and tenascin-C [78]. Periostin secreted by 
airway epithelial cells is able to activate TGF-β-mediated 
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increases in type I collagen production in fibroblasts [86]. 
Periostin can facilitate the infiltration of eosinophils into 
sites of type 2 inflammation [87] and modulate IL-13 and 
IL-5-stimulated eosinophil adhesion and motility, suggest-
ing that periostin may function as a haptotactic stimulus 
able to guide eosinophils to areas of high periostin density 
in the asthmatic airway [88], which may contribute to sus-
tained eosinophil-mediated inflammation and fibrosis.
Persistent upregulation of periostin in the airway epi-
thelium is likely to contribute to mechanisms of increased 
airway fibrosis and decreased airway distensibility [86]. 
Indeed, expression of periostin in airway epithelial cell 
brushings strongly correlates with subepithelial fibrosis in 
asthma [86]. The role of the type 2 inflammatory response 
and IL-13 in subepithelial fibrosis of bronchial asthma is 
also well established [89–92], and this has been reported 
to involve periostin as a downstream component, possibly 
by its binding to other eCM proteins [78]. The functional 
implications of elevated periostin have recently been inves-
tigated. In a Phase II clinical study of subjects with uncon-
trolled asthma, despite inhaled corticosteroids (ICS), it was 
demonstrated that periostin status predicted the response to 
an anti-IL-13 monoclonal antibody, lebrikizumab. Corren 
et al. [81] reported that lebrikizumab significantly improved 
lung function at 12 weeks, and that patients with high pre-
treatment levels of serum periostin had greater improvement 
in lung function than did patients with low periostin levels. 
In a different study (not involving lebrikizumab), follow-
ing assessment of 224 asthmatic patients treated with ICS 
for at least 4 years, Kanemitsu et al. [93] reported that high 
serum periostin was one factor associated with an acceler-
ated decline in Fev1. Polymorphisms of the POSTN gene 
were associated with both raised serum periostin levels and 
a decline in Fev1 ≥ 30 mL/year, indicating that these may 
be useful to identify patients at risk of functional decline.
Furthermore, periostin has been linked with develop-
ment of fibrosis in the pathogenesis of idiopathic interstitial 
pneumonia, and idiopathic pulmonary fibrosis (IPF) [94]. It 
is highly expressed in the lungs and serum of IPF patients 
in whom systemic periostin levels are inversely correlated 
with pulmonary function [95]. It has been suggested that 
periostin acts as an inducer of chemokines in the inflamma-
tory response pivotal for the process of pulmonary fibrosis 
[20].
In addition, periostin has been implicated in atopic con-
ditions such as dermatitis [14, 96] and rhinitis/rhinosinusitis 
[97]. In allergic skin inflammation, periostin induction after 
an initial injury contributes to the establishment of sus-
tained chronic inflammation and tissue remodeling [14]. 
In chronic rhinosinusitis inflammation is mediated by the 
matricellular proteins periostin and osteopontin, leading 
to a proliferative response within the eCM framework and 
largely remodeling of the sinus histopathology [97].
Miscellaneous inflammatory diseases
Increased tissue periostin has been associated with sev-
eral inflammatory conditions, in the fields of eosinophilia 
(e.g., otitis media [98], eosinophilic esophagitis [87]), oph-
thalmology (e.g., proliferative diabetic retinopathy [99]), 
hematology (e.g., bone marrow fibrosis [100]), and fibrotic 
remodeling (e.g., immunoglobulin G4-related sclerosing 
sialadenitis [101] and scleroderma [102]).
Conclusions
In spite of the multiple roles of periostin in health and dis-
ease (Table 1), tissue remodeling as a response to insult/
injury is emerging as a common functional denominator of 
Table 1  Role of periostin in health and disease
NA Not applicable
Tissue/disease Health Disease/repair References
Osteology Intramembranous bone growth,  
bone development, collagen matrix 
formation and mechanotransduction
Fracture repair or response to mechanical stress [19, 29, 30]
Cutaneous and connective  
tissue remodeling
Unknown Muscle repair/regeneration, wound healing [13, 37, 38]
Oncology NA Promote tumor angiogenesis, migration and  
metastases, remodeling tumor microenvironment
[46, 47, 53–55]
Cardiovascular In utero development Response to pressure overload-induced left ventricular 
hypertrophy, repair/remodeling following  
myocardial infarction, repair after vascular injury
[18, 22, 68, 71]
Allergic and respiratory 
diseases
Neonatal lung remodeling Increased airway fibrosis, Th2-driven asthma,  
and eCM protein binding
[76, 78–81, 87]
Other inflammatory diseases NA Proliferation within the eCM framework [97]
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this matricellular molecule. Periostin is transiently upregu-
lated during cell fate changes, either physiologic or patho-
logic. Combining observations across a vast expanse of 
molecular, biological and clinical areas of research, a com-
mon pattern of events may be suggested, including peri-
ostin localization into the area of development/insult, eMT, 
eCM restructuring, and eventually remodeling. Assessing 
the role of periostin by event rather than by disease sug-
gests that any insult/injury such as inflammation, fibrosis, 
or eMT may be associated with a marked elevation of 
periostin levels, regardless of the target tissue or type of 
stimulus.
There is evidence that a periostin-rich microenvironment 
develops in areas associated with insult, such as injury 
and/or inflammation, orchestrating pathways of repair 
and rebuilding [38, 78]. exposure to allergens in atopic 
diseases can be thought of as an insult, similar to what 
occurs in other inflammatory conditions, in which periostin 
expression is associated with remodeling, particularly 
fibrosis and eCM degradation. However, in the presence of 
inappropriately high and/or persisting periostin upregula-
tion in the absence of an insult, an overshoot of the normal 
transient repair process can develop (Fig. 1).
Here, an algorithm may be hypothesized, where the appro-
priate response toward stress/insult is met by a transient 
periostin upregulation in the targeted tissue/organ (Fig. 2). 
If periostin expression is exhausted and/or not adequate, the 
tissue/organ may fail to remodel appropriately, leading to an 
insufficient response (e.g., mice with cardiac hypertrophy 
[70]). In contrast, a sustained upregulation of periostin, such 
as due to a recurring stimulus, could drive remodeling beyond 
the physiologic adaption and perpetuate, by itself, the disease 
state (e.g., mice with chronic skin inflammation [14].
Taken together, we propose mesenchymal remodeling as 
an overarching role for the matricellular protein periostin, 
across physiology and disease. Periostin may be seen as an 
important structural mediator in this remodeling process, 
balancing appropriate versus inappropriate tissue adaption 
in response to insult/injury.
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